Coherus Oncology (CHRS) Projected to Post Earnings on Thursday

Key Points

• Coherus Oncology is set to release its Q2 2025 earnings on August 7th, with analysts predicting an earnings per share of ($0.25) for the quarter.
• Shares of CHRS stock have recently fallen by 6.6% and are currently trading at $0.88, with a market cap of $101.76 million.
• Analysts have varied ratings for Coherus, with HC Wainwright setting a $7.00 price target, while UBS Group lowered its target to $1.05 and Wall Street Zen downgraded it to a "sell" rating.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Coherus Oncology to post earnings of ($0.25) per share for the quarter.

Coherus Oncology (NASDAQ:CHRS - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The firm had revenue of $7.60 million during the quarter, compared to analyst estimates of $59.79 million. During the same quarter in the previous year, the company posted ($0.32) EPS. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Trading Down 6.6%

Shares of CHRS stock opened at $0.88 on Friday. The company's 50-day moving average price is $0.83 and its 200-day moving average price is $0.96. The stock has a market cap of $101.76 million, a price-to-earnings ratio of -0.78 and a beta of 0.89. Coherus Oncology has a twelve month low of $0.66 and a twelve month high of $2.43.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CHRS. HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Coherus Oncology in a research report on Tuesday, April 29th. UBS Group reissued a "neutral" rating and set a $1.05 price target (down previously from $1.50) on shares of Coherus Oncology in a research report on Thursday, April 24th. Finally, Wall Street Zen cut shares of Coherus Oncology from a "hold" rating to a "sell" rating in a research report on Tuesday, May 20th.

Insider Transactions at Coherus Oncology

In related news, Director Mats Wahlstrom sold 99,988 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $0.74, for a total value of $73,991.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 8.08% of the company's stock.

Institutional Trading of Coherus Oncology

An institutional investor recently raised its position in Coherus Oncology stock. Acadian Asset Management LLC boosted its stake in Coherus Oncology, Inc. (NASDAQ:CHRS - Free Report) by 52,980.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 196,927 shares of the biotechnology company's stock after buying an additional 196,556 shares during the period. Acadian Asset Management LLC owned approximately 0.17% of Coherus Oncology worth $158,000 at the end of the most recent quarter. Institutional investors and hedge funds own 72.82% of the company's stock.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.